Business ❯ Finance ❯ Stock Market

Pharmaceutical Stocks

Novo Nordisk Eli Lilly Pfizer Market Reactions Market Performance Tariffs Moderna Eli Lilly and Company AstraZeneca Vertex Pharmaceuticals

Definium's DT120 Shows Rapid, Durable Benefit in Phase 3 Depression Trial

The readout strengthens the company's case for an expedited FDA review as a second confirmatory Phase 3 is completed.

MHRA Approves Oral Wegovy Pill as Novo Nordisk Foundation Launches CardioMetabolic Bridge

Stories older than 24h

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Agrees Three‑Year Phase I/II Data Can Support uniQure’s AMT‑130 Accelerated BLA

Moderna Restructures Leadership as It Prepares for Multiple Vaccine Launches

EMERALD-3 Trial Shows Progression-Free Survival Win for STRIDE Plus Lenvatinib With TACE

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Inhibrx Combo Shows 44% Response vs 21% With Pembrolizumab Alone in First-Line Head and Neck Cancer

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Vertex Posts Mixed Quarter as Profit Beats, Sales Miss and Outlook Holds

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

Lilly’s Foundayo Start Trails Wegovy as Street Stays Positive

Erasca Shares Plunge After Trial Death and Patent Challenge

Cohance Lifesciences Shares Leap After Naming Umang Vohra Executive Chairman and Group CEO

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

BullFrog AI Strikes Top-5 Pharma Deal To Find Depression Drug Targets

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Kodiak’s Zenkuda Hits Phase 3 Goal in Diabetic Retinopathy Prompting Faster FDA Filing

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy